The molecular landscape of HER2− breast cancer is heterogenous.

Allele frequencies of many targetable alterations change early during treatment; PI3K pathway and RTK genes were often altered in those tumors with poor histological response.

Early intensification with addition of targeted agents could benefit these patients.